Drug maker Hetero Group will be investing Rs 1,000 crore to expand its pharmaceutical and specialist business in Andhra Pradesh, its Managaing Director Vamsi Krishna Bandi said on Saturday.
Speaking at Global Investors Summit 2023 here, he said post-Covid pandemic, more countries are looking at India as a partner of choice in pharmaceutical sector, and Andhra Pradesh is ideally placed to take advantage because of a well-established ecosystem.
"We are committed to Andhra Pradesh and will continue to expand our presence here. We'll be investing about Rs 1,000 crore in Andhra Pradesh over the next two years to grow our pharmaceutical and specialty business. This will generate an employment of a minimum of 3,000 people," he said.
Bandi further said the USD 2.5 billion pharma group employs over 10,000 people directly and indirectly in Andhra Pradesh, and supplies about 40 per cent of global HIV medicines that are manufactured in the state.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)